What we do
Stemina is the world leader in building human cellular models for toxicity screening of drug candidates, chemical compounds, cosmetic and tobacco ingredients. Our developmental toxicity assays are the only human system for assessing the risk that a compound will cause birth defects if a woman is exposed during pregnancy.
MORE ABOUT US

What we do

Toxicology

Stemina's toxicology assays are the only human in vitro assays for developmental toxicity screening.

LEARN MORE

Technologies

Stemina's metabolomics platform and expertise in cellular models can be used for custom projects.

LEARN MORE

Our Team

Stemina has assembled a world class team of scientists and experts. Meet our team.

LEARN MORE

Latest news

Oct 25

Stemina to Present a Poster at American College of Toxicology Annual Meeting

Oct 25, 2017
Jessica Palmer, Stemina’s Associate Director of Toxicology, will present a poster at the American College of Toxicology’s 38th Annual Meeting, held November 5-8, 2017 in Palm Springs, California. Anyone interested in cardiotoxicity assays is encouraged to attend. Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Stem Cell-Derived Cardiomyocytes

Read more
Sep 27

Stemina Featured as an Innovative Madison-Area Business

Sep 27, 2017
In collaboration with the Greater Madison Chamber of Commerce, the Wisconsin State Journal produced a special section to “highlight and explore innovation efforts.” Each company’s profile is written by its leader. Stemina’s CEO, Elizabeth Donley, penned our article and also graces the cover of the section. Read Stemina’s profile Explore other companies in the section

Read more
Aug 25

Stemina Biomarker Discovery Prepares to Commercialize Autism Diagnostic Products; Appoints New Board Member, Heiner Dreismann, PhD, Former Head of Roche Molecular Diagnostics

Aug 25, 2017
Dr. Driesmann, a leader in the diagnostics industry, will guide Stemina’s commercialization strategy. Read the full press release.

Read more